E-Prescribing Standards Should Limit Commercial Information, Sen. Grassley Says
This article was originally published in The Pink Sheet Daily
Electronic Rx systems should prevent drug marketing information from influencing physicians’ prescription choices, the Senate Finance Committee chair says in letter to National Committee on Vital & Health Statistics. Pfizer, J&J agree that process should be “neutral and unbiased.”
You may also be interested in...
Physicians should not have to scroll or click through new windows to see non-preferred and off-formulary drugs, Pfizer, J&J tell the standards subcommittee of the National Committee on Vital & Health Statistics.
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.